Phase 3 N=719 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 14.13; 10.74 Months — p=0.0006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=295 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Avoidance of Under-anticoagulation (Peak aFXa <0.2 IU/mL) — 76.6; 79.9 percentage of participants
N/A N=142 A Study to Assess Changes in Cigarette Consumption During a Switch to Very Low Nicotine Cigarettes
Tobacco Use
Primary: Cigarettes Per Day — 14.75; 17.19; 15.76; 16.29 Cigarettes Per Day (CPD)
N/A N=40 Pre-Oxygenation Techniques in Pregnancy
Preoxygenation
Primary: End Tidal Oxygen Concentration (ETO2) Following Tidal Volume Breathing Using Either Face Mask or OptiFlow — 91.0; 87.4 Percentage units of end-tidal oxygen
Phase 2 N=121 Survivorship Promotion In Reducing IGF-1 Trial
Breast Cancer · Prostate Cancer · Lung Cancer
Primary: IGF-1 Levels — 73.2; 73.6; 71.2 ng/ml
N/A N=191 Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism
Astigmatism
Primary: Mean Dioptric Change in Cylinder — -0.479; -0.865; -1.413; -1.944 diopter
N/A N=100 Anaesthesia for Laparoscopic Sleeve Gastrectomy
Obese
Primary: Analgesic Requirements. — 3.56; 1.67 mg
Phase 3 N=495 A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
Erosive Esophagitis
Primary: Recovery Rates of Reflux Esophagitis — 101; 92; 126; 43 Participants — p=0.05
N/A N=371 Prevention of Postpartum Weight Retention in Low Income WIC Women
Obesity
Primary: Weight — -3.2; -0.9 kg — p=<0.0001
Phase 3 N=47 Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome
Ischemic Stroke · Excitotoxicity · Memantine
Primary: Investigation of Neurological Deficit by National Institute of Health Scale Score (NIHSS) — 4.52; 5.75 score on a scale
Phase 2 N=51 Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Epidermolysis Bullosa · Epidermolysis Bullosa Simplex
Primary: Treatment-emergent Adverse Events — 40 Participants
N/A N=225 A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail
Opioid Use Disorder
Primary: Predicted Probability Derived From the Generalized Linear Mixed Model of Opioid Urine Test Positive Results Over Time — 0.70; 0.72; 0.66; 0.59 Probability — p=.32
Phase 2 N=334 Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness — 5; 7; 6; 8 Participants
Phase 2 N=184 Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
Cigarette Smoking
Primary: Number of Participants Smoking-Abstinent for 7 Days, 52 Weeks Post Quit Date — 26; 19 Participants
N/A N=16,231 Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women
Cervical Cancer
Primary: Number of Participants Diagnosed With Cervical Epithelial Neoplasia Grade 2 or Worse — 12; 8 Participants